Nephrotoxicity of amphotericin b in the treatment of cryptococcal meningitis in acquired immunodeficiency syndrome patients

East African Medical Journal

Volumn 86, Issue 9, 2009, Pages 435-441

  Ochieng, P O ^a   Mcligeyo, S O ^b   Amayo, E O ^b   Kayima, J K ^b   Omonge, E O ^b  

^a University of Nairobi ^*  (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; CREATININE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CHEMICALLY INDUCED DISORDER; CRYPTOCOCCAL MENINGITIS; FEMALE; HUMAN; KENYA; KIDNEY DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; CREATININE; FEMALE; HUMANS; KENYA; KIDNEY DISEASES; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77952384322     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. UNAID/WHO. Global summary of HIV/AIDS epidemic. Special report on HIV prevention. December 2007 update; {online}. 2007; Available from URL: http://www.unaid.org/epi/2007/doc/EPIupdate.2005-pdf.
2. Guidelines for ARV Drug Therapy in Kenya. 3rd Edition. Chapter 1, p13. Ministry of health, Republic of Kenya, 2005.
3. French, N.A.B., Gray, K.B., Watera, C.B., et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002; 16: 1031-1038.
4. Jowi, J. O., Mativo, P.M. and Musoke, S. S. Clinical and laboratory characteristics of hospitalized patients with neurological manifestations of HIV/AIDS at the Nairobi Hospital. East Afr. Med. J. 2007; 84: 67-76.
5. Bicanic, T. and Harrison, T. S. Cryptococcal meningitis. Brit. Med. Bull. 2005; 18: 99-118.
6. Branch, R.A. Prevention of Amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch. Intern. Med. 1988; 148:2389-2394.
7. Sawaya, B.P., Briggs, J.P. and Schnermann, J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J. Amer. Soc. Nephrol. 1995; 6:154-164.
8. Butler, W.T., Bennett, J.E., Alling D.W., et al. Nephrotoxicity of Amphotericin B; early and late effects in 81 patients. Ann. Intern. Med. 1964; 61:175-187.
9. Harbarth, S., Pestotnik, S.L., Lloyd, J.F., et al. The epidemiology of nephrotoxicity associated with conventional Amphotericin B therapy. Amer. J. Med. 2001; 111: 528-534.
10. Bates, D.W., Su, L., Yu, D.T., et al. Correlates of acute renal failure in patients receiving parenteral Amphotericin B. Kidney Inter. 2001; 60: 1452-1459.
11. Barton, C.H., Pohl, M., Vaziri, N.D. and Cesario, T. Renal magnesium wasting associated with Amphotericin B therapy. Amer. J. Med. 1984; 77:471-474.
12. Harbarth, S., Burke, J.P., Lloyd, J.F., et al. Clinical and economic outcomes of conventional Amphotericin B-associated nephrotoxicity. Clin. Infect. Dis. 2002; 35: 120-127.
13. Ullmann, A.J., Sanz, M.A, Tramarin, A., et al. Prospective study of Amphotericin B formulations in immunocompromised patients in 4 European countries. Clin. Infect. Dis. 2006; 43: 29-38.
14. Susan, H. Amphotericin B-related nephrotoxicity increases hospital stay in immunocompromised patients. Cancer weekly, September 26, 2006.
15. Heidemann, H.T., Gerkens, J.F., Spickard, W.A., et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Amer. J. Med. 1983; 75: 476-483.
16. Sacks, P. and Fellner, S.K. Recurrent reversible acute renal failure from Amphotericin B. Arch. Intern. Med. 1987; 147:593-595.
17. Clements, J. S. and Peacock J. E. Amphotericin B revisited: reassessment of toxicity. Amer. J. Med. 1990. 88 Suppl. 5N: 22N-27N.
18. Luber, A.D., Maa, L., Lam, M. and Guglielmo J. B. Risk factors for Amphotericin B induced nephrotoxicity. J. Antimicrob. Chemother.1999; 43: 267-271.
19. Benson, J.M. and Nahata, M.C. Pharmacokinetics of Amphotericin B in children. Antimicrob. Agents Chemother. 1989; 33: 1989-1993.
20. Walsh, T.J., Finberg, RW., Arndt, C., et al. Liposomal Amphotericin B for empirical therapy in patients with persistent fever and neutropenia National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 1999; 340:764-771.
21. Wingard, J.R., Kubilis, P., Lee, L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 1999; 29:1402-1407.
22. Prentice, H.G., Harm, L.M., Herbrecht, R., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 1997; 98:711-718.
23. White, M.H., Bowden, R.A., Sandler, E., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 1998; 27:296-302.
24. Herbrecht, R., Denning, D.W., Patterson, T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002; 347: 408-415.
25. Mora-Duarte, J., Betts, R., Rotstein, C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 2002; 347: 2020-2029.
26. Kullberg, B.J., Sobel, J.D., Ruhnke, M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005; 366: 1435-1442.
27. Bates, D.W., Su, L., Yu, D.T., et al. Mortality and cost of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 2001; 32:686-693.
28. Chien-Yuan, Chen, Ritesh, N., Kumar, Yin-Hsun Feng, et al. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. J. Antimicrob. Chemother. 2006; 57: 1181-1188.
29. Girmenia, C, Gentile, G., Micozzi, A., et al. Nephrotoxicity of amphotericin B desoxycholate. Clin. Infect. Dis. 2001; 33: 915-916.
30. Girmenia, C., Cimino, G., Micozzi, A., et al. Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. 2002; 113:351.
31. Pathak, A., Pien, F. D. and Carvalho, L. Amphotericin B use in a community hospital, with special emphasis on side effects. Clin. J. Infect. Dis. 1998; 26:334-338.
32. Sanford, W. G., Rasch, J. R. and Stonehill, R. B. A therapeutic dilemma: the treatment of disseminated coccidioidomycosis with amphotericin B. Ann. Intern. Med. 1962; 56: 553-563.
33. Miller, R.P. and Bates, J.R. Amphotericin B toxicity: a follow-up report of 53 patients. Ann. Intern. Med. 1969; 71: 1089-1095.
34. Medoff, G., Dismukes, W.E., Meade, R.H. III and Moses, J.M. A new therapeutic approach to Candida infections: a preliminary report. Arch. Intern. Med. 1972; 130: 241-245.
35. Gross, M.H., Pickard, W.W. and Perfect, J.R. Retrospective review of amphotericin use in a tertiary-care medical center. Am. J. Hosp. Pharm. 1987; 44: 1353-1357.
36. Anaissie, E.J., Vartivarian, S.E., Abi-Said, D., et al. Fluconazole vs. amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. 1996; 101: 170-176.
37. Whang, R., Whang, D.D. and Ryan, M.P. Refractory potassium depletion. A consequence of magnesium deficiency. Arch. Intern. Med. 1992; 152:40-45.